Chronic Kidney Disease Clinical Trial
Official title:
The Prevention Contrast-Induced Acute Kidney Injury With the Triple Combination of Hydration With Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate
Contrast-Induced Acute Kidney Injury(CIAKI) was defined as an absolute increase in serum
creatinine of more than or equal to 0.3mg/dl (≥ 26.4 μmol/l), a percentage increase in serum
creatinine of more than or equal to 50% (1.5-fold from baseline) within 48 hours of
intravascular contrast administration in the absence of any alternative causes, or a
reduction in urine output documented oliguria of less than 0.5 ml/kg per hour for more than
six hours.
It is the common cause of new hospital-acquired renal insufficiency. The occurrence of CIAKI
may be influenced by pre-existing renal insufficiency, diabetic nephropathy, dehydration,
congestive heart failure, concurrent administration of nephrotoxic drugs, or the dose and
type of contrast media used. Previous studies have shown the independent effectiveness of
several agents in preventing CIAKI.
Even now, hydration is crucial for preventing CIAKI. Since CIAKI is presumed to be caused by
free radical generation, N-Acetylcysteine, which is a potent free radical scavenger, is
shown to be effective in preventing nephropathy. At the same time, because free radical
formation is promoted by an acidic environment, bicarbonate, which alkalinizes renal tubular
fluid, has been shown to reduce renal involvement.
These days, some studies have shown that hydration with sodium bicarbonate plus
N-Acetylcysteine was effective and safe in the prevention of CIAKI. In these studies,
bicarbonate was used for both alkalinizing renal tubular fluid and hydration. However, if we
want to do hydration, we can use saline and if we want to alkalinize renal tubular fluid, we
might use bicarbonate by bolus injection.
Actually, bicarbonate for hydration is prepared at sterile preparation room in a hospital,
which is very cumbersome procedure and increase in cost. This is one of the reasons that
bicarbonate for hydration use does not become common with wide clinical application.
In past issues, though it differs depending on the level of the renal dysfunction, the
probability of CIAKI was 8-33% when hydration was administered, 5-15% when hydration and
N-Acetylcysteine were administered, and 1.8-1.9% when bicarbonate and N-Acetylcysteine were
administered.
Thus, we can hypothesize the combination of N-Acetylcysteine and bicarbonate will play a
complementary role in preventing contrast-induced nephropathy.
This is the rational for this study.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |